Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 4
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Circulating CD137+ T Cell Levels Are Correlated with Response to Pembrolizumab Treatment in Advanced Head and Neck Cancer Patients.
Cirillo A, Zizzari IG, Botticelli A, Strigari L, Rahimi H, Scagnoli S, Scirocchi F, Pernazza A, Pace A, Cerbelli B, d'Amati G, Marchetti P, Nuti M, Rughetti A, Napoletano C. Cirillo A, et al. Among authors: scirocchi f. Int J Mol Sci. 2023 Apr 12;24(8):7114. doi: 10.3390/ijms24087114. Int J Mol Sci. 2023. PMID: 37108276 Free PMC article.
Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib.
Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari IG, Nuti M, Rughetti A. Scirocchi F, et al. Front Oncol. 2021 Oct 20;11:755433. doi: 10.3389/fonc.2021.755433. eCollection 2021. Front Oncol. 2021. PMID: 34745989 Free PMC article.
Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Zizzari IG, Di Filippo A, Botticelli A, Strigari L, Pernazza A, Rullo E, Pignataro MG, Ugolini A, Scirocchi F, Di Pietro FR, Rossi E, Gelibter A, Schinzari G, D'Amati G, Rughetti A, Marchetti P, Nuti M, Napoletano C. Zizzari IG, et al. Among authors: scirocchi f. Clin Cancer Res. 2022 Mar 1;28(5):1027-1037. doi: 10.1158/1078-0432.CCR-21-2918. Clin Cancer Res. 2022. PMID: 34980602 Free PMC article.
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: Relief from immunosuppression is associated with clinical response.
Scirocchi F, Scagnoli S, Botticelli A, Di Filippo A, Napoletano C, Zizzari IG, Strigari L, Tomao S, Cortesi E, Rughetti A, Marchetti P, Nuti M. Scirocchi F, et al. EBioMedicine. 2022 May;79:104010. doi: 10.1016/j.ebiom.2022.104010. Epub 2022 Apr 25. EBioMedicine. 2022. PMID: 35477069 Free PMC article.
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients.
Zizzari IG, Di Filippo A, Scirocchi F, Di Pietro FR, Rahimi H, Ugolini A, Scagnoli S, Vernocchi P, Del Chierico F, Putignani L, Rughetti A, Marchetti P, Nuti M, Botticelli A, Napoletano C. Zizzari IG, et al. Among authors: scirocchi f. J Pers Med. 2020 Nov 4;10(4):208. doi: 10.3390/jpm10040208. J Pers Med. 2020. PMID: 33158018 Free PMC article.
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line.
Gelibter A, Asquino A, Strigari L, Zizzari IG, Tuosto L, Scirocchi F, Pace A, Siringo M, Tramontano E, Bianchini S, Bellati F, Botticelli A, Paoli D, Santini D, Nuti M, Rughetti A, Napoletano C. Gelibter A, et al. Among authors: scirocchi f. J Transl Med. 2024 Apr 3;22(1):329. doi: 10.1186/s12967-024-05142-6. J Transl Med. 2024. PMID: 38570798 Free PMC article.